Form 4: Anika Therapeutics SVP Anne Nunes Reports Stock Transactions
SEC Form 4
Anne Nunes, SVP and Chief Operations Officer of Anika Therapeutics, reports the vesting of RSUs and subsequent stock transactions.
Summary
- On March 11, 2025, Anne Nunes, SVP, Chief Operations Officer of Anika Therapeutics, had 2,561 Restricted Stock Units (RSUs) vest.
- Ms. Nunes disposed of 752 shares to cover tax withholding obligations at a price of $16.79 per share.
- Following these transactions, Ms. Nunes directly owns 18,085 shares of Anika Therapeutics common stock.
- The vesting represents the final installment of RSUs granted on March 11, 2022, which vested in three equal annual installments beginning March 11, 2023.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock transactions related to executive compensation.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 03/11/2022 | Date of original RSU grant. |
| 03/11/2023 | First vesting date of RSUs. |
| 03/11/2025 | Date of RSU vesting and stock transactions. |
| 03/13/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.